FealtySign in

BRISTOL MYERS SQUIBB CO

(BMY)

CIK 14272 · SEC filings only

Not gradedDividend record
shown as history
company entity
66 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

66 declarations · 17 raised · 48 held · 0 cut · held 65 quarters

  1. HELD$0.6300/shperiod ended 2026-06-30Filing ↗
  2. RAISED$0.6300/shperiod ended 2026-03-31Filing ↗
  3. HELD$0.6200/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.6200/shperiod ended 2025-06-30Filing ↗
  5. RAISED$0.6200/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.6000/shperiod ended 2024-09-30Filing ↗
  7. HELD$0.6000/shperiod ended 2024-06-30Filing ↗
  8. RAISED$0.6000/shperiod ended 2024-03-31Filing ↗
  9. HELD$0.5700/shperiod ended 2023-09-30Filing ↗
  10. HELD$0.5700/shperiod ended 2023-06-30Filing ↗
  11. RAISED$0.5700/shperiod ended 2023-03-31Filing ↗
  12. HELD$0.5400/shperiod ended 2022-09-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
B+Buyback record
grade
company entity
6 resolved promises

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Open promises (1)

Open · buyback authorization

$4 billion accelerated share repurchase program

unresolved — no outcome on file$4.00Breceipt (opens in a new tab)

Credibility timeline

KEPT · Feb 25, 2019KEPT · Apr 29, 2022KEPT · Apr 27, 2023KEPT · Apr 27, 2023PARTIAL · Apr 25, 2024KEPT · Jul 26, 2024
20192024
Timeline as a list
  • Feb 25, 2019KEPTBristol-Myers Squibb today announced its Board of Directors approved a new $3 billion repurchase authorization for the Company’s common stock.
  • Apr 29, 2022KEPTincreases the company’s total outstanding share repurchase authorization under the company’s share repurchase program to approximately $6 billion
  • Apr 27, 2023KEPTDuring 2021, the company plans to repurchase $3.0-$4.0 billion of its shares
  • Apr 27, 2023KEPTauthorized incremental share repurchases of up to an additional $2 billion
  • Apr 25, 2024PARTIALauthorized an additional $15 billion, multi-year share repurchase program
  • Jul 26, 2024KEPTrepurchase $5 billion of Bristol Myers Squibb common stock
6 resolved buyback promises · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
DGuidance record
grade
company entity
13 resolved promises

Sector median (Life Sciences): B across 7 graded companies

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

12 of 25 guidance figures that were graded or dropped for basis could not be graded on the same basis (48%). Guidance marked “not judged” is in neither number.

Guidance typeSaidGradedDroppedOther
Revenue · GAAP1100
Revenue · non-GAAPcannot be graded110110
Revenue · basis not stated193016
EPS · GAAP259016
EPS · non-GAAPcannot be graded3701126

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (49)

We show what was said — with its source filing — but never score it. The line under each statement says why.

  1. revenue guidance fy · Jul 30, 2026
    Bristol Myers Squibb is increasing its full-year, non-GAAP revenue guidance from a range of approximately $46.0 billion to $47.5 billion to a range of approximately $49.0 billion to $50.0 billion
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Jul 30, 2026
    non-GAAP EPS is increasing to an anticipated range of $6.75 - $7.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Apr 30, 2026
    Non-GAAP EPS range of $6.05 to $6.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. revenue guidance fy · Apr 30, 2026
    revenues of ~$46.0 billion to $47.5 billion
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. revenue guidance fy · Feb 5, 2026
    The company estimates total revenues will be approximately $46.0 billion to $47.5 billion
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Feb 5, 2026
    Non-GAAP EPS range of $6.05 to $6.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Oct 30, 2025
    Non-GAAP EPS is now expected to be in the range of $6.40 - $6.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. revenue guidance fy · Oct 30, 2025
    Raising 2025 revenue guidance to a range of ~$47.5 billion to $48.0 billion
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. revenue guidance fy · Jul 31, 2025
    Raising 2025 revenue guidance to a range of ~$46.5 billion to $47.5 billion
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Jul 31, 2025
    Non-GAAP EPS is now expected to be in the range of $6.35 - $6.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Apr 24, 2025
    the company is raising the midpoint of its 2025 non-GAAP EPS guidance by $0.15 per share to an expected range of $6.70 to $7.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. revenue guidance fy · Apr 24, 2025
    The company is increasing its full-year revenue guidance from approximately $45.5 billion to a range of approximately $45.8 billion to $46.8 billion
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Feb 6, 2025
    Non-GAAP EPS Range of $6.55 to $6.85
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. revenue guidance fy · Feb 6, 2025
    We estimate total revenues to be approximately $45.5 billion
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Oct 31, 2024
    $0.75 - $0.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Jul 26, 2024
    $0.60 - $0.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. revenue guidance fy · Jul 26, 2024
    Low single-digit increase
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Apr 25, 2024
    Revised Diluted EPS $0.40 - $0.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. revenue guidance fy · Apr 25, 2024
    Total Revenues Low single-digit increase
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. revenue guidance fy · Feb 2, 2024
    Total 2024 revenues are expected to increase by low single-digits
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Feb 2, 2024
    Bristol Myers Squibb provides its 2024 non-GAAP EPS guidance range of $7.10 - $7.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · Jul 27, 2023
    $7.35-$7.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance fy · Apr 27, 2023
    $7.95-$8.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · Feb 2, 2023
    its non-GAAP EPS guidance range of $7.95 - $8.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · Oct 26, 2022
    $7.44-$7.74
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Jul 27, 2022
    $7.44 - $7.74
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. revenue guidance fy · Jul 27, 2022
    In-line Products & New Product Portfolio ~$36.5 billion or Low double-digit increase
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  28. eps guidance fy · Apr 29, 2022
    $2.92 - $3.22
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. eps guidance fy · Feb 4, 2022
    reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. eps guidance fy · Oct 27, 2021
    its non-GAAP EPS guidance range of $7.35 - $7.55 to $7.40 - $7.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. eps guidance fy · Jul 28, 2021
    reaffirming its non-GAAP EPS guidance range of $7.35 - $7.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  32. eps guidance fy · Apr 29, 2021
    affirming its non-GAAP EPS guidance range of $7.35 - $7.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  33. eps guidance fy · Feb 4, 2021
    is increasing its non-GAAP EPS guidance range from $7.15 - $7.45 to $7.35 - $7.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  34. eps guidance fy · Nov 5, 2020
    reaffirming its 2021 non-GAAP EPS guidance range of $7.15 to $7.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  35. eps guidance fy · Nov 5, 2020
    the company is raising its 2020 non-GAAP EPS guidance range from $6.10 - $6.25 to $6.25 - $6.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  36. eps guidance fy · May 7, 2020
    affirming its 2020 non-GAAP EPS guidance range of $6.00 to $6.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  37. eps guidance fy · May 7, 2020
    2021 non-GAAP EPS guidance range of $7.15 to $7.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  38. eps guidance fy · Feb 6, 2020
    non-GAAP EPS guidance range of $6.00 to $6.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  39. eps guidance fy · Feb 6, 2020
    non-GAAP EPS guidance range of $7.15 to $7.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  40. eps guidance fy · Jul 25, 2019
    increasing its non-GAAP EPS guidance range from $4.10 - $4.20 to $4.20 - $4.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  41. eps guidance fy · Jul 26, 2018
    increasing its non-GAAP EPS guidance range from $3.35 - $3.45 to $3.55 - $3.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  42. eps guidance fy · Feb 5, 2018
    non-GAAP EPS guidance range at $3.15 to $3.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  43. eps guidance fy · Jul 27, 2017
    raising the lower end of its non-GAAP EPS guidance range from $2.85 - $3.00 to $2.90 - $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  44. eps guidance fy · Jan 26, 2017
    Adjusts Non-GAAP EPS Guidance Range to $2.70 to $2.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  45. eps guidance fy · Oct 27, 2016
    non-GAAP EPS between $2.85 and $3.05.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  46. eps guidance fy · Oct 27, 2016
    The company is increasing its non-GAAP EPS guidance range from $2.55 - $2.65 to $2.80 - $2.90.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  47. revenue guidance fy · Apr 28, 2016
    Worldwide revenues increasing in the low-double digit range
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  48. eps guidance fy · Apr 28, 2016
    Non-GAAP EPS Guidance Range to $2.50 - $2.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  49. eps guidance fy · Oct 27, 2015
    Increases Non-GAAP EPS Guidance Range to $1.85 - $1.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (7) · 24 superseded

Open · revenue guidance fy

Worldwide revenues increasing in the high-teens.

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

Worldwide revenues increasing in the low-single digits

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

Worldwide revenues increasing in the mid- to high-single digits

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

Worldwide revenues increasing in the mid-single digits

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

Worldwide revenues increasing in the high-single digits

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

Low single digit decline

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

Upper end of low single-digit range

unresolved — no outcome on filereceipt (opens in a new tab)
Superseded · revenue guidance fy

Total revenues are expected to increase by approximately 2% at reported rates and approximately 2% excluding foreign exchange

revised by a later guidance$2.0000receipt (opens in a new tab)
Superseded · eps guidance fy

Bristol Myers Squibb provides its 2023 GAAP EPS guidance range of $4.03 - $4.33

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Bristol-Myers Squibb is providing 2020 GAAP EPS guidance range of $0.75 to $0.95

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Worldwide revenues increasing in the high-single digits

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Bristol Myers Squibb is providing 2021 GAAP EPS guidance in the range of $3.12-$3.32

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Bristol Myers Squibb is updating its 2021 GAAP EPS guidance range of $3.12-$3.32 to $3.18-$3.38

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

$3.37 - $3.67

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

low single-digit increase

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

updating its 2021 GAAP EPS guidance range of $3.18 - $3.38 to $2.77 - $2.97

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Diluted EPS $4.03-$4.33

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

2019 GAAP EPS Guidance Range of $3.75 to $3.85

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Bristol-Myers Squibb is setting its 2018 GAAP EPS guidance range at $3.00 to $3.15

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

$2.92 - $3.22 $2.71 - $3.01

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Confirms 2017 GAAP EPS Guidance Range of $2.47 to $2.67

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Bristol-Myers Squibb expects 2017 GAAP EPS between $2.47 and $2.67

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Increases 2016 GAAP EPS Guidance Range to $2.37 - $2.47

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Worldwide revenues increasing in the high-single digits

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Worldwide revenues are expected to be approximately $47 billion

revised by a later guidance$47.0000receipt (opens in a new tab)
Superseded · eps guidance fy

$3.72-$4.02

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Worldwide revenues increasing in the high-single digits

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Worldwide revenues increasing in the low- to mid-single digits

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Total Net Sales In-line with 2021 $46.0 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Adjusts 2020 GAAP EPS Guidance Range to $0.37-$0.57

revised by a later guidancereceipt (opens in a new tab)

Credibility timeline

ABOVE · Feb 12, 2016IN LINE · Feb 21, 2017BELOW · Feb 13, 2018ABOVE · Feb 25, 2019BELOW · Feb 24, 2020BELOW · Feb 10, 2021ABOVE · Feb 10, 2021ABOVE · Feb 9, 2022IN LINE · Feb 14, 2023ABOVE · Feb 14, 2023ABOVE · Feb 13, 2024BELOW · Feb 13, 2024
20162024
Timeline as a list
  • Feb 12, 2016ABOVEWorldwide revenues between $16.0 and $16.4 billion
  • Feb 21, 2017IN LINEBristol-Myers Squibb is increasing its 2016 GAAP EPS guidance range from $2.43 - $2.53 to $2.62 - $2.72.
  • Feb 13, 2018BELOWupdating its 2017 GAAP EPS guidance range from $2.72 - $2.87 to $2.66 - $2.76
  • Feb 25, 2019ABOVEdecreasing its 2018 GAAP EPS guidance range from $2.70 - $2.80 to $2.68 - $2.78
  • Feb 24, 2020BELOWdecreasing its 2019 GAAP EPS guidance range from $3.84 - $3.94 to $3.73- $3.83
  • Feb 10, 2021BELOWBristol Myers Squibb is increasing its 2020 GAAP EPS guidance range from ($0.06) - $0.09 to $0.47 - $0.57
  • Feb 10, 2021ABOVERevenue $40.0B - $42.0B
  • Feb 9, 2022ABOVEBristol Myers Squibb is updating its 2021 GAAP EPS guidance range of $2.77 - $2.97 to $2.68 - $2.83
  • Feb 14, 2023IN LINETotal Sales ~$46.0 billion
  • Feb 14, 2023ABOVE$2.54-$2.84
  • Feb 13, 2024ABOVEAdjusting GAAP diluted EPS range to $3.68-$3.83
  • Feb 13, 2024BELOWTotal Revenues (as reported) ~2% increase
13 resolved guidance promises · 49 not graded (no comparable reported figure) · resolver resolver-v5 · score score-v1. Every verdict links to its source filing. Full methodology →